Contact Us
Drug Search Results
More Filters [+]

Talabostat

Alternative Names: talabostat, bxcl-701, bxcl701, bxcl 701
Latest Update: 2024-11-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DPP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Prostate Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: DARA BioSciences|Midatech Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Talabostat

Countries in Clinic: United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Adenocarcinoma|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Prostate Cancer|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
EXPEL PANC

P2

Recruiting

Pancreatic Ductal Carcinoma|Pancreatic Cancer|Adenocarcinoma

2026-11-01

BXCL701-201

P2

Active, not recruiting

Small Cell Lung Cancer|Adenocarcinoma|Prostate Cancer|Neuroendocrine Carcinoma|Neuroendocrine Tumors

2023-10-01

57%

Recent News Events

Date

Type

Title

11/12/2024

News Article

 BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia

10/29/2024

News Article

 BioXcel Therapeutics to Present at ThinkEquity Conference

10/15/2024

News Article

 BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

09/05/2024

News Article

 BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

03/25/2024

PubMed

 DPP Inhibition Enhances the Efficacy of PD-1 Blockade by Remodeling the Tumor Microenvironment in Lewis Lung Carcinoma Model.

11/01/2023

PubMed

 Pembrolizumab in mCRPC - Combination therapies as breakthrough to success?

03/21/2023

PubMed

 Transformable prodrug nanoplatform via tumor microenvironment modulation and immune checkpoint blockade potentiates immunogenic cell death mediated cancer immunotherapy.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions